Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
